Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
December 3, 2021

EMA begins rolling review of Valneva’s Covid-19 vaccine candidate VLA2001

The European Medicines Agency (EMA) has begun a rolling review of Valneva’s VLA2001, a whole-virus inactivated, adjuvanted Covid-19 vaccine candidate.

The firm is undertaking laboratory development and testing of new variants at its facilities in France and Austria. Credit: ronstik from Pixabay